Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Innovative Pharmaceutical Biotech ( (HK:0399) ) has issued an update.
Starcoin Group Limited has signed a new memorandum of understanding with NASDAQ-listed Newbridge Acquisition Limited and Conflux Foundation to explore a potential de-SPAC transaction involving the group, Conflux and their respective assets or businesses, replacing an earlier MOU with Newbridge alone. The contemplated deal is expected to give Starcoin access to U.S. capital markets for fundraising and to integrate Conflux’s blockchain infrastructure and digital asset technology, which the board believes would strengthen its blockchain initiatives, enhance operational reliability and unlock greater value for shareholders if the transaction proceeds to completion.
The most recent analyst rating on (HK:0399) stock is a Sell with a HK$0.18 price target. To see the full list of analyst forecasts on Innovative Pharmaceutical Biotech stock, see the HK:0399 Stock Forecast page.
More about Innovative Pharmaceutical Biotech
Starcoin Group Limited, formerly Innovative Pharmaceutical Biotech Limited, operates through subsidiaries with a strategic focus on blockchain infrastructure and related digital asset technologies. The group is positioning itself to leverage public-chain ecosystems and smart contract management capabilities to enhance its blockchain-related initiatives and overall value proposition.
Average Trading Volume: 39,257,002
Technical Sentiment Signal: Hold
Current Market Cap: HK$400.7M
Find detailed analytics on 0399 stock on TipRanks’ Stock Analysis page.